DK2911700T5 - The drug-protein conjugates - Google Patents

The drug-protein conjugates Download PDF

Info

Publication number
DK2911700T5
DK2911700T5 DK13786530.9T DK13786530T DK2911700T5 DK 2911700 T5 DK2911700 T5 DK 2911700T5 DK 13786530 T DK13786530 T DK 13786530T DK 2911700 T5 DK2911700 T5 DK 2911700T5
Authority
DK
Denmark
Prior art keywords
group
conjugate
val
auristatin
antibody
Prior art date
Application number
DK13786530.9T
Other languages
Danish (da)
English (en)
Other versions
DK2911700T3 (en
Inventor
John Burt
Antony Godwin
Mark Frigerio
George Badescu
Original Assignee
Polytherics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2013/051593 external-priority patent/WO2013190292A2/en
Application filed by Polytherics Ltd filed Critical Polytherics Ltd
Application granted granted Critical
Publication of DK2911700T3 publication Critical patent/DK2911700T3/en
Publication of DK2911700T5 publication Critical patent/DK2911700T5/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
DK13786530.9T 2012-10-24 2013-10-11 The drug-protein conjugates DK2911700T5 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261717743P 2012-10-24 2012-10-24
US201261717710P 2012-10-24 2012-10-24
US201361811285P 2013-04-12 2013-04-12
PCT/GB2013/051593 WO2013190292A2 (en) 2012-06-19 2013-06-19 Novel process for preparation of antibody conjugates and novel antibody conjugates
PCT/GB2013/052661 WO2014064423A1 (en) 2012-10-24 2013-10-11 Drug-protein conjugates

Publications (2)

Publication Number Publication Date
DK2911700T3 DK2911700T3 (en) 2017-05-15
DK2911700T5 true DK2911700T5 (en) 2017-05-22

Family

ID=50544085

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13786530.9T DK2911700T5 (en) 2012-10-24 2013-10-11 The drug-protein conjugates

Country Status (18)

Country Link
US (2) US20150290342A1 (enExample)
EP (2) EP2911700B1 (enExample)
JP (1) JP6328648B2 (enExample)
KR (1) KR102209395B1 (enExample)
CN (1) CN104870021B (enExample)
AU (1) AU2013336409B2 (enExample)
BR (1) BR112015008376A2 (enExample)
CA (1) CA2884299A1 (enExample)
DK (1) DK2911700T5 (enExample)
ES (1) ES2623209T3 (enExample)
IL (1) IL237672B (enExample)
IN (1) IN2015DN02349A (enExample)
MX (1) MX2015005122A (enExample)
MY (1) MY169147A (enExample)
RU (1) RU2015119561A (enExample)
SG (1) SG11201501618WA (enExample)
WO (1) WO2014064423A1 (enExample)
ZA (1) ZA201501642B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015030514A2 (pt) * 2013-06-04 2017-08-29 Cytomx Therapeutics Inc Composições e métodos para conjugação de anticorpos ativáveis
AU2014337555C1 (en) 2013-10-15 2021-01-28 Seagen Inc. PEGylated drug-linkers for improved Ligand-Drug Conjugate pharmacokinetics
EP3145552B1 (en) * 2014-05-23 2020-03-04 Novartis AG Methods for making conjugates from disulfide-containing proteins
RU2728235C2 (ru) * 2014-06-12 2020-07-28 СиЭсПиСи ДОФЕН КОРПОРЕЙШН Конъюгат антитела и лекарственного средства, композиции на его основе и способы их получения
WO2016059377A1 (en) * 2014-10-14 2016-04-21 Polytherics Limited Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of peg
ES2960741T3 (es) * 2014-10-24 2024-03-06 Abzena Uk Ltd Conjugados y reactivos de conjugación
GB201419108D0 (en) 2014-10-27 2014-12-10 Glythera Ltd Materials and methods relating to linkers for use in antibody drug conjugates
CN107029242A (zh) 2015-11-03 2017-08-11 财团法人工业技术研究院 抗体药物复合物及其制造方法
TWI852735B (zh) 2015-12-04 2024-08-11 美商思進公司 四級胺化妥布賴森(tubulysin)化合物之結合物
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
KR102626498B1 (ko) 2016-03-25 2024-01-19 씨젠 인크. 페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정
WO2017178828A1 (en) * 2016-04-14 2017-10-19 Polytherics Limited Conjugates and conjugating reagents comprising a linker that includes at least two (-ch2-ch2-0-) units in a ring
GB201608936D0 (en) * 2016-05-20 2016-07-06 Polytherics Ltd Novel conjugates and novel conjugating reagents
US11485792B2 (en) * 2016-06-06 2022-11-01 Polytherics Limited Antibodies, uses thereof and conjugates thereof
GB201614162D0 (en) 2016-08-18 2016-10-05 Polytherics Ltd Antibodies, uses thereof and conjugates thereof
US11730822B2 (en) 2017-03-24 2023-08-22 Seagen Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
GB201820864D0 (en) * 2018-12-20 2019-02-06 J A Kemp Antibody-drug conjugates
WO2021209007A1 (en) * 2020-04-15 2021-10-21 Shenzhen Enduring Biotech, Ltd. Antibody-drug conjugate
CN115702004A (zh) * 2021-03-19 2023-02-14 深圳康源久远生物技术有限公司 具有cd3和cd19双重特异性的聚乙二醇化t细胞衔接器
US20250222124A1 (en) * 2022-01-27 2025-07-10 Glyco-Therapy Biotechnology Co., Ltd. Protein conjugates with multiple payloads and methods for making the same
TW202444426A (zh) * 2023-03-29 2024-11-16 美商艾克塞里克斯公司 Amhrii抗體-藥物結合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
EP3434275A1 (en) * 2003-11-06 2019-01-30 Seattle Genetics, Inc. Assay for cancer cells based on the use of auristatin conjugates with antibodies
AU2006294554B2 (en) * 2005-09-26 2013-03-21 E. R. Squibb & Sons, L.L.C. Antibody-drug conjugates and methods of use
WO2009052431A2 (en) * 2007-10-19 2009-04-23 Seattle Genetics, Inc. Cd19 binding agents and uses thereof
EP2265283B1 (en) 2008-03-18 2014-09-03 Seattle Genetics, Inc. Auristatin drug linker conjugates
RU2487877C2 (ru) * 2008-04-30 2013-07-20 Иммьюноджен, Инк. Высокоэффективные конъюгаты и гидрофильные сшивающие агенты (линкеры)
US9005598B2 (en) 2009-03-04 2015-04-14 Polytherics Limited Conjugated proteins and peptides
CA2757382A1 (en) * 2009-04-01 2010-10-21 Kristi Elkins Anti-fcrh5 antibodies and immunoconjugates
UY32913A (es) * 2009-10-02 2011-04-29 Sanofi Aventis Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuero
US9995804B2 (en) * 2012-04-25 2018-06-12 Koninklijke Philips N.V. System and method for locating a gradient coil
SG11201407600UA (en) * 2012-06-19 2014-12-30 Polytherics Ltd Novel process for preparation of antibody conjugates and novel antibody conjugates

Also Published As

Publication number Publication date
RU2015119561A (ru) 2016-12-20
JP2015533847A (ja) 2015-11-26
IL237672A0 (en) 2015-04-30
MY169147A (en) 2019-02-18
EP3159013A1 (en) 2017-04-26
US20220062436A1 (en) 2022-03-03
SG11201501618WA (en) 2015-04-29
ES2623209T3 (es) 2017-07-10
IN2015DN02349A (enExample) 2015-08-28
CN104870021A (zh) 2015-08-26
ZA201501642B (en) 2016-01-27
WO2014064423A1 (en) 2014-05-01
AU2013336409A1 (en) 2015-04-02
EP2911700A1 (en) 2015-09-02
KR102209395B1 (ko) 2021-01-28
IL237672B (en) 2018-02-28
EP2911700B1 (en) 2017-02-08
DK2911700T3 (en) 2017-05-15
MX2015005122A (es) 2015-10-29
US20150290342A1 (en) 2015-10-15
KR20150103656A (ko) 2015-09-11
JP6328648B2 (ja) 2018-05-23
CA2884299A1 (en) 2014-05-01
AU2013336409B2 (en) 2017-08-03
CN104870021B (zh) 2018-03-13
BR112015008376A2 (pt) 2017-09-26
HK1208187A1 (en) 2016-02-26

Similar Documents

Publication Publication Date Title
DK2911700T3 (en) The drug-protein conjugates
DK2911696T3 (en) Drug-protein conjugates
KR101988005B1 (ko) 개선된 연결을 갖는 아마톡신-접합체
US20200392108A1 (en) Antibody-drug conjugates and related compounds, compositions and methods
KR20230008723A (ko) 전하 변이체 링커
AU2013279099A1 (en) Novel process for preparation of antibody conjugates and novel antibody conjugates
AU2015340370A1 (en) Materials and methods relating to linkers for use in protein drug conjugates
HK1232455A1 (en) Drug-protein conjugates
HK1232455A (en) Drug-protein conjugates
HK1208187B (en) Drug-protein conjugates
HK1208186B (en) Drug-protein conjugates